Glioblastoma CUSA Fluid Protein Profiling: A Comparative Investigation of the Core and Peripheral Tumor Zones.

CUSA fluid brain tumor glioblastoma multiforme proteomics

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
23 12 2020
Historique:
received: 05 11 2020
revised: 04 12 2020
accepted: 18 12 2020
entrez: 30 12 2020
pubmed: 31 12 2020
medline: 31 12 2020
Statut: epublish

Résumé

The present investigation aimed to characterize the protein profile of cavitating ultrasound aspirator fluid of newly diagnosed and recurrent glioblastoma comparing diverse zones of collection, i.e., tumor core and tumor periphery, with the aid of 5-aminolevulinic acid fluorescence. The samples were pooled and analyzed in triplicate by LC-MS following the shotgun proteomic approach. The identified proteins were then grouped to disclose elements exclusive and common to the tumor state or tumor zones and submitted to gene ontology classification and pathway overrepresentation analysis. The proteins common to the distinct zones were further investigated by relative quantitation, following a label free approach, to disclose possible differences of expression. Nine proteins, i.e., tubulin 2B chain, CD59, far upstream element-binding, CD44, histone H1.4, caldesmon, osteopontin, tropomyosin chain and metallothionein-2, marked the core of newly diagnosed glioblastoma with respect to tumor periphery. Considering the tumor zone, including the core and the fluorescence positive periphery, the serine glycine biosynthesis, pentose phosphate, 5-hydroxytryptamine degredation, de novo purine biosynthesis and huntington disease pathways resulted statistically significantly overrepresented with respect to the human genome of reference. The fluorescence negative zone shared several protein elements with the tumor zone, possibly indicating the presence of pathological aspects of glioblastoma rather than of normal brain parenchyma. On the other hand, its exclusive protein elements were considered to represent the healthy zone and, accordingly, exhibiting no pathways overrepresentation. On the contrary to newly diagnosed glioblastoma, pathway overrepresentation was recognized only in the healthy zone of recurrent glioblastoma. The TGFβ signaling pathway, exclusively classified in the fluorescence negative periphery in newly diagnosed glioblastoma, was instead the exclusive pathway classified in the tumor core of recurrent glioblastoma. These results, preliminary obtained on sample pools, demonstrated the potential of cavitron ultrasonic sur.

Identifiants

pubmed: 33374813
pii: cancers13010030
doi: 10.3390/cancers13010030
pmc: PMC7795841
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cell Stem Cell. 2014 Mar 6;14(3):357-69
pubmed: 24607407
Cancers (Basel). 2020 Oct 13;12(10):
pubmed: 33066172
Nucleic Acids Res. 2017 Jan 4;45(D1):D183-D189
pubmed: 27899595
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
J Proteome Res. 2016 Nov 4;15(11):3961-3970
pubmed: 27490519
Curr Neuropharmacol. 2012 Mar;10(1):72-9
pubmed: 22942880
Brain Res Mol Brain Res. 1996 Sep 5;41(1-2):1-7
pubmed: 8883928
Prog Neurobiol. 2010 Aug;91(4):313-48
pubmed: 20438797
Neuro Oncol. 2010 Jun;12(6):528-39
pubmed: 20156804
Front Immunol. 2020 Jan 21;10:3137
pubmed: 32038644
Sci Rep. 2019 Apr 1;9(1):5406
pubmed: 30932010
Clin Nutr Res. 2018 Jul;7(3):153-160
pubmed: 30079313
Int J Clin Exp Pathol. 2015 Jul 01;8(7):7825-37
pubmed: 26339347
Ann Bot. 2011 May;107(7):1127-40
pubmed: 21169293
Am J Pathol. 2004 Jun;164(6):2217-28
pubmed: 15161654
Neuro Oncol. 2016 Sep;18(9):1219-29
pubmed: 26917237
Oncogene. 2020 Jun;39(23):4477-4490
pubmed: 32366909
Neurosurgery. 2020 Jun 1;86(6):E529-E540
pubmed: 32186345
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Proteomics. 2019 Jan;19(1-2):e1800157
pubmed: 30451371
Neuroreport. 2001 Sep 17;12(13):2845-8
pubmed: 11588588
Oncotarget. 2017 Oct 19;8(57):97304-97312
pubmed: 29228611
Medicina (Kaunas). 2019 Jul 27;55(8):
pubmed: 31357616
PLoS One. 2017 May 31;12(5):e0178277
pubmed: 28562655
J Clin Invest. 2019 Jan 2;129(1):137-149
pubmed: 30307407
BMC Bioinformatics. 2017 Mar 2;18(1):142
pubmed: 28249561
J Neurosurg Sci. 2019 Dec;63(6):619-624
pubmed: 31961115
PLoS Genet. 2010 Dec 23;6(12):e1001257
pubmed: 21203498
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Cancers (Basel). 2013 Apr 03;5(2):357-71
pubmed: 24216981
Lab Invest. 2020 Jun;100(6):812-823
pubmed: 31949244
Surg Technol Int. 2018 Nov 11;33:353-360
pubmed: 30117132
Clin Neurol Neurosurg. 2018 Jul;170:120-126
pubmed: 29777944
J Neurooncol. 2017 Jan;131(2):233-244
pubmed: 27770278
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Expert Rev Proteomics. 2014 Oct;11(5):621-39
pubmed: 25115191
J Cell Sci. 2003 Aug 1;116(Pt 15):3051-60
pubmed: 12829735
Cell Rep. 2016 Dec 6;17(10):2607-2619
pubmed: 27926865
J Neurosurg Sci. 2020 Feb 04;:
pubmed: 32031360
J Hematol Oncol. 2018 Aug 23;11(1):107
pubmed: 30139373
World Neurosurg. 2019 Sep;129:401-403
pubmed: 31229752
Future Oncol. 2018 Apr;14(8):781-791
pubmed: 29521526
Crit Rev Clin Lab Sci. 2019 Dec 22;:1-26
pubmed: 31865806
Nat Neurosci. 2017 May;20(5):661-673
pubmed: 28346452
Heliyon. 2018 Jul 18;4(7):e00695
pubmed: 30094365
J Clin Neurosci. 2016 Dec;34:1-5
pubmed: 27578526
Exp Mol Med. 2018 Apr 6;50(4):5
pubmed: 29622771
Clin Neurol Neurosurg. 2020 Nov;198:106105
pubmed: 32739680
Cells. 2019 Aug 09;8(8):
pubmed: 31405017
Cancers (Basel). 2019 Apr 03;11(4):
pubmed: 30987226
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931

Auteurs

Giuseppe La La Rocca (G)

Department of Neurosurgery, Mater Olbia Hospital, 07026 Olbia, Italy.

Giorgia Antonia Simboli (GA)

Institute of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, 00168 Rome, Italy.

Federica Vincenzoni (F)

Dipartimento di Scienze Biotecnologiche di Dase, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.

Diana Valeria Rossetti (DV)

Dipartimento di Scienze Biotecnologiche di Dase, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.

Andrea Urbani (A)

Dipartimento di Scienze Biotecnologiche di Dase, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.

Tamara Ius (T)

Neurosurgery Unit, Department of Neurosciences, University Hospital of Udine, 33100 Udine, Italy.

Giuseppe Maria Della Pepa (GM)

Institute of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, 00168 Rome, Italy.

Alessandro Olivi (A)

Institute of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, 00168 Rome, Italy.

Giovanni Sabatino (G)

Department of Neurosurgery, Mater Olbia Hospital, 07026 Olbia, Italy.

Claudia Desiderio (C)

Istituto di Scienze e Tecnologie Chimiche "Giulio Natta", Consiglio Nazionale delle Ricerche, 00168 Roma, Italy.

Classifications MeSH